The CPCT Genomics Core enables UMass Boston investigators and academic and industry collaborators to carry out basic and translational genomics research. The Core leverages cutting-edge technologies and next-generation sequencing capabilities for research and clinical applications. We help investigators and clinicians analyze samples, identify genetic variants contributing to disease risk, and reveal complex mechanisms involved in human disease.

The Core offers cost-effective massively parallel sequencing with the Illumina HiSeq 2500 (v4, 1TB enabled) and Illumina MiSeq platforms; 10X Genomics Chromium Single Cell Sequencing Platform; Nanostring nCounter Analysis System; next-generation sequencing library preparation from RNA and DNA, and nucleic acid quality assessments using Bioanalyzer, Tapestation, Nanodrop and Qubit assays. Additional instruments include a Biomek FXp automated workstation, and a QuantStudio 12K Flex Real-Time PCR System.

The Center for Personalized Cancer Therapy is a collaborative venture between the University of Massachusetts Boston and the Dana Farber/Harvard Cancer Center (DF/HCC) and funded by the Massachusetts Life Sciences Center.